Similar articles

• Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?

  Jung YK, Kim JH. Jung YK, et al. Clin Mol Hepatol. 2013 Mar;19(1):26-8. doi: 10.3350/cmh.2013.19.1.26. Epub 2013 Mar 25. Clin Mol Hepatol. 2013. PMID: 23593606 Free PMC article. No abstract available.
• Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients.

  Chung WJ. Chung WJ. Clin Mol Hepatol. 2012 Sep;18(3):268-71. doi: 10.3350/cmh.2012.18.3.268. Epub 2012 Sep 25. Clin Mol Hepatol. 2012. PMID: 23091806 Free PMC article. No abstract available.
• [Is 24 weeks of peginterferon and ribavirin combination therapy sufficient for the patients with genotype 1 chronic hepatitis C?].

  Song BC. Song BC. Korean J Gastroenterol. 2010 Jul;56(1):59-61. doi: 10.4166/kjg.2010.56.1.59. Korean J Gastroenterol. 2010. PMID: 20664319 Korean. No abstract available.
• Peginterferon and ribavirin for chronic hepatitis C.

  Hoofnagle JH, Seeff LB. Hoofnagle JH, et al. N Engl J Med. 2006 Dec 7;355(23):2444-51. doi: 10.1056/NEJMct061675. N Engl J Med. 2006. PMID: 17151366 Review. No abstract available.
• Spotlight on peginterferon-alpha-2a (40 kD) plus ribavirin in the management of chronic hepatitis C mono-infection.

  Keam SJ, Cvetković RS. Keam SJ, et al. BioDrugs. 2009;23(1):63-8. doi: 10.2165/00063030-200923010-00007. BioDrugs. 2009. PMID: 19344193 Review.